黏蛋白与黏液性卵巢癌：发生、鉴别诊断及治疗
Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.
作者信息
Wang Yicong, Liu Lifeng, Yu Yongai
机构信息
Department of Obstetrics and Gynecology, Dalian Municipal Central Hospital, Dalian, China.
出版信息
Heliyon. 2023 Aug 17;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221. eCollection 2023 Aug.
Abstract
Mucinous ovarian carcinoma (MOC) is a rare histological type of epithelial ovarian cancer. It has poor response to conventional platinum-based chemotherapy regimens and PARPi-based maintenance treatment, resulting in short survival and poor prognosis in advanced-disease patients. MOC is characterized by mucus that is mainly composed of mucin in the cystic cavity. Our review discusses in detail the role of mucins in MOC. Mucins are correlated with MOC development. Furthermore, they are valuable in the differential diagnosis of primary and secondary ovarian mucinous tumors. Some types of mucins have been studied in the context of chemoresistance and targeted therapy for ovarian cancer. This review may provide a new direction for the diagnosis and treatment of advanced MOC.
摘要
黏液性卵巢癌（MOC）是上皮性卵巢癌中一种罕见的组织学类型。它对传统的铂类化疗方案和基于PARPi的维持治疗反应不佳，导致晚期疾病患者生存期短且预后不良。MOC的特征是囊肿腔内主要由黏蛋白组成的黏液。我们的综述详细讨论了黏蛋白在MOC中的作用。黏蛋白与MOC的发生相关。此外，它们在原发性和继发性卵巢黏液性肿瘤的鉴别诊断中具有重要价值。一些类型的黏蛋白已在卵巢癌的化疗耐药性和靶向治疗方面进行了研究。本综述可能为晚期MOC的诊断和治疗提供新的方向。
相似文献
1
Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment.黏蛋白与黏液性卵巢癌：发生、鉴别诊断及治疗
Heliyon. 2023 Aug 17;9(8):e19221. doi: 10.1016/j.heliyon.2023.e19221. eCollection 2023 Aug.
2
Mucinous Cancer of the Ovary: Overview and Current Status.卵巢黏液性癌：概述与现状
Diagnostics (Basel). 2020 Jan 19;10(1):52. doi: 10.3390/diagnostics10010052.
3
Survival of Patients With Mucinous Ovarian Carcinoma and Ovarian Metastases: A Population-Based Cancer Registry Study.黏液性卵巢癌和卵巢转移患者的生存情况：一项基于人群的癌症登记研究
Int J Gynecol Cancer. 2015 Sep;25(7):1208-15. doi: 10.1097/IGC.0000000000000473.
4
Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer.黏液性卵巢癌预后和预测标志物的最新进展
Cancers (Basel). 2023 Feb 12;15(4):1172. doi: 10.3390/cancers15041172.
5
Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma.黏液性交界性卵巢肿瘤和黏液性卵巢癌的特征及腹腔热灌注化疗的回顾性研究
Gland Surg. 2023 Apr 28;12(4):453-464. doi: 10.21037/gs-23-45. Epub 2023 Apr 13.
6
Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.黏液性卵巢肿瘤的组织学分类：观察者间的可重复性、临床相关性和遗传生物标志物的作用。
Virchows Arch. 2021 May;478(5):885-891. doi: 10.1007/s00428-020-02939-w. Epub 2020 Oct 3.
7
Options for the Treatment of Mucinous Ovarian Carcinoma.黏液性卵巢癌的治疗选择
Curr Treat Options Oncol. 2021 Nov 13;22(12):114. doi: 10.1007/s11864-021-00904-6.
8
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).MUC4在卵巢癌中的异常表达：单独及与MUC1和MUC16（CA125）联合的诊断意义
Mod Pathol. 2006 Oct;19(10):1386-94. doi: 10.1038/modpathol.3800646. Epub 2006 Jul 28.
9
Presentation and Prognosis of Primary Expansile and Infiltrative Mucinous Carcinomas of the Ovary.原发性扩张性和浸润性卵巢黏液性癌的临床表现及预后
J Clin Med. 2022 Oct 17;11(20):6120. doi: 10.3390/jcm11206120.
10
Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach.黏液性卵巢癌的多模态诊断策略与精准医学：一种综合方法
Front Oncol. 2024 Jul 8;14:1391910. doi: 10.3389/fonc.2024.1391910. eCollection 2024.
引用本文的文献
1
Mucinous Ovarian Carcinoma: Integrating Molecular Stratification into Surgical and Therapeutic Management.黏液性卵巢癌：将分子分层纳入手术和治疗管理
Biomedicines. 2025 May 14;13(5):1198. doi: 10.3390/biomedicines13051198.
2
The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials.巨噬细胞极化在卵巢癌中的作用：从分子机制到治疗潜力
Front Immunol. 2025 Apr 22;16:1543096. doi: 10.3389/fimmu.2025.1543096. eCollection 2025.
3
Rare leptomeningeal recurrence of mucinous ovarian carcinoma.黏液性卵巢癌罕见的软脑膜复发
Gynecol Oncol Rep. 2025 Apr 19;59:101749. doi: 10.1016/j.gore.2025.101749. eCollection 2025 Jun.
4
Postoperative metastatic Krukenberg tumors with and mutations in a patient with gastric cancer treated with oxaliplatin and tegafur: A case report.奥沙利铂和替加氟治疗的胃癌患者术后发生伴有 和 突变的转移性克鲁肯贝格瘤：一例报告
Oncol Lett. 2025 Apr 2;29(6):262. doi: 10.3892/ol.2025.15008. eCollection 2025 Jun.
5
A 33.5 cm Mucinous Ovarian Carcinoma and Associated Comorbidities in an 89-Year-Old Female.一名89岁女性的33.5厘米黏液性卵巢癌及相关合并症
Cureus. 2024 Aug 27;16(8):e67970. doi: 10.7759/cureus.67970. eCollection 2024 Aug.
6
Management of open abdomen complication after laparotomy in an ovarian cancer patient with intraperitoneal metastasis.一名患有腹膜转移的卵巢癌患者剖腹术后开放性腹腔并发症的处理
J Surg Case Rep. 2024 Aug 6;2024(8):rjae482. doi: 10.1093/jscr/rjae482. eCollection 2024 Aug.
7
Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.卵巢癌中的致癌途径和靶向治疗。
Biomolecules. 2024 May 15;14(5):585. doi: 10.3390/biom14050585.
本文引用的文献
1
Mucin networks: Dynamic structural assemblies controlling mucus function.黏蛋白网络：控制黏液功能的动态结构组件。
Curr Opin Struct Biol. 2023 Apr;79:102524. doi: 10.1016/j.sbi.2022.102524. Epub 2023 Feb 6.
2
Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.Claudin18.2 作为原发性卵巢黏液性癌和源自上消化道原发性肿瘤的转移性卵巢黏液性癌的潜在治疗靶点。
BMC Cancer. 2023 Jan 13;23(1):44. doi: 10.1186/s12885-023-10533-x.
3
Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials.黏液性卵巢癌的靶向治疗：来自临床试验的证据。
Int J Gynecol Cancer. 2023 Jan 3;33(1):102-108. doi: 10.1136/ijgc-2022-003658.
4
Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes.黏蛋白 13（MUC13）作为卵巢癌检测的候选生物标志物：在检测非浆液性亚型方面有补充 CA125 的潜力。
Clin Chem Lab Med. 2022 Nov 17;61(3):464-472. doi: 10.1515/cclm-2022-0491. Print 2023 Feb 23.
5
A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.联合应用免疫组化标志物 MUC1、MUC5AC、PAX8 及生长方式对卵巢黏液性肿瘤进行特征性描述。
Int J Gynecol Cancer. 2022 May 3;32(5):662-668. doi: 10.1136/ijgc-2021-003104.
6
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.抗肿瘤相关粘蛋白 1 抗体 gatipotuzumab 用于复发性上皮性卵巢癌患者的维持治疗：一项双盲、安慰剂对照、随机、Ⅱ期研究结果。
ESMO Open. 2022 Feb;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 15.
7
Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary.原发性黏液性卵巢癌的预后：重点关注五种提示卵巢转移性黏液性癌的病理发现。
J Gynecol Oncol. 2022 Mar;33(2):e18. doi: 10.3802/jgo.2022.33.e18. Epub 2021 Dec 6.
8
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.一项在铂类耐药卵巢癌患者中进行的 DMUC4064A 的开放性、I 期剂量递增研究，评估其安全性和药代动力学。
Gynecol Oncol. 2021 Dec;163(3):473-480. doi: 10.1016/j.ygyno.2021.09.023. Epub 2021 Oct 6.
9
Decreased Gastric Gland Mucin-specific -glycans Are Involved in the Progression of Ovarian Primary Mucinous Tumours.胃腺粘蛋白特异性聚糖减少与卵巢原发性黏液性肿瘤的进展有关。
Acta Histochem Cytochem. 2021 Aug 25;54(4):115-122. doi: 10.1267/ahc.21-00032. Epub 2021 Jul 7.
10
MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer.黏蛋白 5AC 的表达与卵巢癌的黏液性/子宫内膜样亚型、无淋巴结转移和错配修复缺陷有关。
Pathol Res Pract. 2021 Aug;224:153533. doi: 10.1016/j.prp.2021.153533. Epub 2021 Jun 21.
Zotero 插件